Navigation Links
Boston Scientific Announces Results for Third Quarter Ended September 30, 2008
Date:10/21/2008

p> of two payments the Company expects to receive as a result of Guidant's

sale of its vascular intervention and endovascular solutions businesses

to Abbott and are not indicative of future operating results. Purchased

research and development is a highly variable charge based on valuation

assumptions. Management removes the impact of purchased research and

development from the Company's operating results to assist in assessing

the Company's operating performance and cash generated from operations.

The integration costs associated with the Company's acquisition of

Guidant do not reflect expected on-going future operating expenses. The

fair value adjustment related to the sharing of proceeds feature of the

Abbott stock purchase is a non-cash adjustment and is not indicative of

the Company's on-going operations. Accordingly, management excluded

these charges and gains for purposes of calculating these non-GAAP

measures to facilitate an evaluation of the Company's current operating

performance and a comparison to the Company's past operating

performance.

-- Restructuring-related charges - These adjustments primarily represent

severance, employee-related retention incentives, asset write-offs and

accelerated depreciation and other costs associated with the Company's

restructuring initiatives. These expenses are not indicative of the

Company's on-going operating performance and are excluded by management

in assessing the Company's operating performance, and are also excluded

from the Company's operating segments' measures of profit and loss used

for making operating decisions and assessing performance. Accordingly,

management excluded these charges for purposes of calculating these

non-GAAP measures to facilitate an evaluation of the Company's curren
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Related biology technology :

1. Boston Scientific Provides Comments Reinforcing Strength of Its Balance Sheet
2. Boston Scientific Provides Update on Involuntary Selling of Its Stock by Co-Founders
3. Video: Boston Scientific Announces FDA Approval of Second-Generation TAXUS(R) Liberte(R) Drug-Eluting Stent
4. Boston Scientific Announces FDA Approval of TAXUS(R) Express2(TM) Atom(TM) Stent System, First Drug-Eluting Stent For Small Vessels
5. Boston Scientific to Participate in UBS Global Life Sciences Conference
6. Boston Scientific Announces Court Decision
7. IBC Life Sciences Kicks Off the 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress in Boston, Massachusetts
8. InNexus Biotechnology CEO and Chief Scientific Officer to Present at IBCs Annual World Congress Conference in Boston on Aug 6th
9. NorthPoint Domain and Boston Medical Center Partner to Apply Advanced Patient Engagement Instruments to Pioneering Cardiac Robotic Surgery Program
10. TechCFO Adds Gary Strickland as Partner in Boston Office
11. Boston Scientific Announces FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... MA (PRWEB) September 02, 2014 ... today the signage of a distribution agreement with ... is now distributing Myriant’s bio-succinic acid in the ... and Ireland, targeting customers in the industrial and ... distribution powerhouse, Azelis offers a far-reaching chemical portfolio ...
(Date:9/2/2014)... Inc. (Nasdaq: ONTY ) announced today that ... present at the Rodman & Renshaw 16 th Annual ... on Tuesday, Sept. 9, 2014 at 2:05 p.m. Eastern. ... will be accessible by visiting the Oncothyreon website www.oncothyreon.com ... About Oncothyreon Oncothyreon is a biotechnology company ...
(Date:9/2/2014)... 2014  Spherix Incorporated (SPEX) -- an intellectual property development company ... today announced that the United States Patent & Trademark ... the month of August that are part of a ... issued patents are: , U.S.RE45,065 issued ... 2014; and , U.S.RE45,095 issued August 26, 2014.  ...
(Date:9/1/2014)... The global oligonucleotide synthesis market is expected ... million in 2014, growing at a CAGR of ... synthesis market is categorized on the basis of ... The synthesized oligonucleotides segment is expected to register ... market during the forecast period, owing to an ...
Breaking Biology Technology:Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2United States Patent & Trademark Office Issues Three New Standard Essential Patents to Spherix 29.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 29.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 39.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 49.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 5
... Mass., Sept. 19 Boston Scientific,Corporation (NYSE: BSX ... Life,Sciences Conference, which is being held September 22 - ... Chief Executive Officer, will make a,30-minute presentation which will ... Thursday, September 25, beginning at approximately 9:00,a.m. ET., ...
... PARK, Ill., Sept. 19 Abbott (NYSE:,ABT) will announce ... before the market opens., The announcement will be ... at 8 a.m. Central time (9 a.m. Eastern), and ... http://www.abbottinvestor.com . An archived edition of the call will ...
... China, Sept. 19 /Xinhua-PRNewswire-FirstCall/ --,China-Biotics, Inc. (OTC ... Chinese firm specializing in the manufacture,research, development, ... that at its 2008 Annual General Meeting ... the Company,s nominees to the,Board of Directors., ...
Cached Biology Technology:China-Biotics, Inc. Announces Results of 2008 Annual General Meeting of Shareholders 2
(Date:9/2/2014)... distribution of media will have lower carbon emissions ... file sizes are large. , That,s the conclusion ... of Industrial Ecology that looked at the ... PlayStation3. Researchers found that Blu-ray Discs delivered via ... game files downloaded over broadband Internet. For their ...
(Date:9/2/2014)... New research suggests that professional baseball pitchers with poor core ... in a single season because of injury than are pitchers ... and pelvis. , In the study, 347 pitchers were assessed ... in their pelvis as they raised a leg to step ... at least 30 days cumulative, not consecutive during ...
(Date:9/2/2014)... new study published in the September issue of ... identifies a novel strategy to diagnose the leading ... irreversible structural damage has occurred. This advance involves ... on the endothelium of retinal vessels. Using new ... distinguish the early molecular development of diabetic retinopathy. ...
Breaking Biology News(10 mins):In pro baseball pitchers, weak core linked to more missed days 2In pro baseball pitchers, weak core linked to more missed days 3Molecular probes permit doctors to detect diabetic retinopathy before vision fails 2
... for hundreds of years as an herbal remedy to prevent ... commonly used herbal medicines in North America. However, in spite ... on the body,s immune system are conflicting. ... University Indianapolis are investigating the possibility that Echinacea has other ...
... 20 million people in the U.S., and many more worldwide, ... developing mesothelioma, a malignant cancer of the membranes that cover ... Moreover, asbestos exposure increases the risk of lung cancer among ... understand why asbestos causes cancer. The answer ...
... Tuesday 29 June 2010, announces this year,s award winners ... to theoretical physicist Professor Edward Witten for outstanding, transformative ... influential physicists of the past 30 years, he has ... particle physics and cosmology to theoretical areas of string ...
Cached Biology News:Mystery unraveled: How asbestos causes cancer 2IOP announces 2010 award winners 2